Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
HTGMQ
HTG Molecular Diagnostics
$0.00
$0.00
$0.01
N/A2.731,510 shsN/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
$0.00
$0.00
$0.00
$0.13
$6K-6.3812,829 shsN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$0.01
$0.09
$0.01
$5.17
$22K2.786,249 shs77 shs
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
$0.00
$0.00
$0.30
$1K1.184,517 shsN/A
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
HTGMQ
HTG Molecular Diagnostics
0.00%0.00%0.00%0.00%-50.00%
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
0.00%0.00%0.00%-72.73%-99.75%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00%-45.45%-45.45%-76.00%-99.65%
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
0.00%0.00%0.00%0.00%-99.95%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/AN/AN/AN/AN/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
N/AN/AN/AN/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/AN/AN/AN/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
HTGMQ
HTG Molecular Diagnostics
0.00
N/AN/AN/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
0.00
N/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
0.00
N/AN/AN/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
0.00
N/AN/AN/A
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
HTGMQ
HTG Molecular Diagnostics
$6.37M0.00N/AN/AN/ANaN
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
N/AN/AN/AN/A($1.77) per shareN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
$225.09M0.00N/AN/A$0.14 per share0.09
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
$9.61M0.00N/AN/A($0.99) per share0.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
HTGMQ
HTG Molecular Diagnostics
-$21.59MN/A0.00N/AN/AN/AN/AN/AN/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
$8.95MN/A0.00N/AN/A-81.22%304.57%N/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
-$47.72M-$28.20N/AN/A-336.59%N/A-61.89%11/5/2025 (Estimated)
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
-$17.98M-$5.14N/AN/AN/AN/AN/AN/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/AN/AN/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
N/AN/AN/AN/AN/A
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/AN/AN/AN/AN/A
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
HTGMQ
HTG Molecular Diagnostics
N/AN/AN/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
N/A
0.03
0.02
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
N/A
1.23
1.06
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
N/AN/AN/A

Institutional Ownership

CompanyInstitutional Ownership
HTGMQ
HTG Molecular Diagnostics
N/A
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
26.55%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
37.63%
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
5.78%

Insider Ownership

CompanyInsider Ownership
HTGMQ
HTG Molecular Diagnostics
2.60%
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
25.40%
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
24.50%
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
78.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
HTGMQ
HTG Molecular Diagnostics
902.21 million2.16 millionNot Optionable
Spectaire Holdings Inc. stock logo
SPEC
Spectaire
818.41 million13.74 millionNot Optionable
Telesis Bio, Inc. stock logo
TBIO
Telesis Bio
2001.80 million1.36 millionOptionable
ThermoGenesis Holdings, Inc. stock logo
THMO
ThermoGenesis
407.95 million1.75 millionNot Optionable

Recent News About These Companies

North American Morning Briefing: Stock Futures, -2-
Why Is ThermoGenesis (THMO) Stock Down 37% Today?
ThermoGenesis Holdings, Inc.
ThermoGenesis Holdings Recent Insider Activity
ThermoGenesis Q3 Earnings Preview
Here's what Wall Street expects from ThermoGenesis's earnings report
ThermoGenesis Holdings Inc THMO

HTG Molecular Diagnostics NASDAQ:HTGMQ

HTG Molecular Diagnostics, Inc. a life sciences company, focuses on the precision medicine. The company offers instruments; consumables; and software that automate sample processing and profiles various molecular targets. Its marketed molecular profiling panels include HTG Transcriptome Panel; HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq Oncology Biomarker Panel; HTG immune response panel; and HTG mouse mRNA tumor response panel. The company distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona. On June 5, 2023, HTG Molecular Diagnostics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

Spectaire stock logo

Spectaire NASDAQ:SPEC

$0.0003 0.00 (0.00%)
As of 08/29/2025

Spectaire Holdings Inc. provides solutions that measure, manage, and reduce carbon dioxide equivalent and other greenhouse gas emissions. The company offers AireCore, an integrated hardware, software, and data platform for logistics and supply chain players that uses mass spectrometry to directly measure their emissions. It serves the logistics, energy, agriculture, academics, and indoor air industries. The company is based in Watertown, Massachusetts.

Telesis Bio stock logo

Telesis Bio NASDAQ:TBIO

$0.01 0.00 (0.00%)
As of 08/29/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

ThermoGenesis stock logo

ThermoGenesis NASDAQ:THMO

ThermoGenesis Holdings, Inc. develops, commercializes, and markets a range of automated technologies for cell-banking, cell-processing, and cell-based therapeutics in the United States, China, the United Arab Emirates, Vietnam, and internationally. The company provides medical device products for automated cell processing. Its clinical bio-banking applications include AXP II Automated Cell Separation System, an automated fully closed cell separation system for isolating stem and progenitor cells from umbilical cord blood; and BioArchive Automated Cryopreservation System, an automated, robotic, liquid nitrogen controlled-rate-freezing and cryogenic storage system for cord blood samples and cell therapeutic products used in clinical applications. The company's point-of-care applications include XP Point-of-Care System, an automated, fully closed, sterile system that allows for the rapid and automated processing of autologous peripheral blood or bone marrow aspirate derived stem cells at the point-of-care, such as surgical centers or clinics; and PXP-1000 System, an automated, fully closed system that provides fast, reproducible separation of multiple cellular components from blood with minimal red blood cell contamination. Its cell processing products comprise X-Series products for general laboratory use, such as X-Lab for cell isolation, X-Wash System for cell washing and reformulation, and X-Mini for high efficiency small scale cell purification. The company also provides contract development and manufacturing services for cell and cell-based gene therapies. It markets and sells its medical device products through independent distributors, as well as direct to end-user customers. The company was formerly known as Cesca Therapeutics Inc. and changed its name to ThermoGenesis Holdings, Inc. in November 2019. ThermoGenesis Holdings, Inc. was incorporated in 1986 and is headquartered in Rancho Cordova, California.